Enzymatic assay for quantitative analysis of (D)-2-hydroxyglutarate - PubMed (original) (raw)
. 2012 Dec;124(6):883-91.
doi: 10.1007/s00401-012-1060-y. Epub 2012 Nov 2.
Affiliations
- PMID: 23117877
- DOI: 10.1007/s00401-012-1060-y
Enzymatic assay for quantitative analysis of (D)-2-hydroxyglutarate
Jörg Balss et al. Acta Neuropathol. 2012 Dec.
Abstract
Levels of (D)-2-hydroxyglutarate [D2HG, (R)-2-hydroxyglutarate] are increased in some metabolic diseases and in neoplasms with mutations in the isocitrate dehydrogenase 1 (IDH1) and isocitrate dehydrogenase 2 (IDH2) genes. Determination of D2HG is of relevance to diagnosis and monitoring of disease. Standard detection methods of D2HG levels are liquid-chromatography-mass spectrometry or gas-chromatography-mass spectrometry. Here we present a rapid, inexpensive and sensitive enzymatic assay for the detection of D2HG levels. The assay is based on the conversion of D2HG to α-ketoglutarate (αKG) in the presence of the enzyme (D)-2-hydroxyglutarate dehydrogenase (HGDH) and nicotinamide adenine dinucleotide (NAD(+)). Determination of D2HG concentration is based on the detection of stoichiometrically generated NADH. The quantification limit of the enzymatic assay for D2HG in tumor tissue is 0.44 μM and in serum 2.77 μM. These limits enable detection of basal D2HG levels in human tumor tissues and serum without IDH mutations. Levels of D2HG in frozen and paraffin-embedded tumor tissues containing IDH mutations or in serum from acute myeloid leukemia patients with IDH mutations are significantly higher and can be easily identified with this assay. In conclusion, the assay presented is useful for differentiating basal from elevated D2HG levels in tumor tissue, serum, urine, cultured cells and culture supernatants.
Similar articles
- Pretreatment d-2-hydroxyglutarate serum levels negatively impact on outcome in IDH1-mutated acute myeloid leukemia.
Balss J, Thiede C, Bochtler T, Okun JG, Saadati M, Benner A, Pusch S, Ehninger G, Schaich M, Ho AD, von Deimling A, Krämer A, Heilig CE. Balss J, et al. Leukemia. 2016 Apr;30(4):782-8. doi: 10.1038/leu.2015.317. Epub 2015 Nov 19. Leukemia. 2016. PMID: 26582645 Clinical Trial. - Metabolic syndromes and malignant transformation: where the twain shall meet.
Bhagwat N, Levine RL. Bhagwat N, et al. Sci Transl Med. 2010 Oct 20;2(54):54ps50. doi: 10.1126/scitranslmed.3001669. Sci Transl Med. 2010. PMID: 20962328 - IDH mutations in glioma and acute myeloid leukemia.
Dang L, Jin S, Su SM. Dang L, et al. Trends Mol Med. 2010 Sep;16(9):387-97. doi: 10.1016/j.molmed.2010.07.002. Epub 2010 Aug 5. Trends Mol Med. 2010. PMID: 20692206 Review. - Oncogenic isocitrate dehydrogenase mutations: mechanisms, models, and clinical opportunities.
Cairns RA, Mak TW. Cairns RA, et al. Cancer Discov. 2013 Jul;3(7):730-41. doi: 10.1158/2159-8290.CD-13-0083. Epub 2013 Jun 24. Cancer Discov. 2013. PMID: 23796461 Review. - Molecular mechanisms of isocitrate dehydrogenase 1 (IDH1) mutations identified in tumors: The role of size and hydrophobicity at residue 132 on catalytic efficiency.
Avellaneda Matteo D, Grunseth AJ, Gonzalez ER, Anselmo SL, Kennedy MA, Moman P, Scott DA, Hoang A, Sohl CD. Avellaneda Matteo D, et al. J Biol Chem. 2017 May 12;292(19):7971-7983. doi: 10.1074/jbc.M117.776179. Epub 2017 Mar 22. J Biol Chem. 2017. PMID: 28330869 Free PMC article.
Cited by
- Proximity ligation assay evaluates IDH1R132H presentation in gliomas.
Bunse L, Schumacher T, Sahm F, Pusch S, Oezen I, Rauschenbach K, Gonzalez M, Solecki G, Osswald M, Capper D, Wiestler B, Winkler F, Herold-Mende C, von Deimling A, Wick W, Platten M. Bunse L, et al. J Clin Invest. 2015 Feb;125(2):593-606. doi: 10.1172/JCI77780. Epub 2015 Jan 2. J Clin Invest. 2015. PMID: 25555220 Free PMC article. Clinical Trial. - An Enzymatic Biosensor for the Detection of D-2-Hydroxyglutaric Acid in Serum and Urine.
Wu B, Li Z, Kang Z, Ma C, Song H, Lu F, Zhu Z. Wu B, et al. Biosensors (Basel). 2022 Jan 25;12(2):66. doi: 10.3390/bios12020066. Biosensors (Basel). 2022. PMID: 35200327 Free PMC article. - D-2-Hydroxyglutarate producing neo-enzymatic activity inversely correlates with frequency of the type of isocitrate dehydrogenase 1 mutations found in glioma.
Pusch S, Schweizer L, Beck AC, Lehmler JM, Weissert S, Balss J, Miller AK, von Deimling A. Pusch S, et al. Acta Neuropathol Commun. 2014 Feb 14;2:19. doi: 10.1186/2051-5960-2-19. Acta Neuropathol Commun. 2014. PMID: 24529257 Free PMC article. - Beyond Brooding on Oncometabolic Havoc in IDH-Mutant Gliomas and AML: Current and Future Therapeutic Strategies.
Madala HR, Punganuru SR, Arutla V, Misra S, Thomas TJ, Srivenugopal KS. Madala HR, et al. Cancers (Basel). 2018 Feb 11;10(2):49. doi: 10.3390/cancers10020049. Cancers (Basel). 2018. PMID: 29439493 Free PMC article. Review. - Pretreatment d-2-hydroxyglutarate serum levels negatively impact on outcome in IDH1-mutated acute myeloid leukemia.
Balss J, Thiede C, Bochtler T, Okun JG, Saadati M, Benner A, Pusch S, Ehninger G, Schaich M, Ho AD, von Deimling A, Krämer A, Heilig CE. Balss J, et al. Leukemia. 2016 Apr;30(4):782-8. doi: 10.1038/leu.2015.317. Epub 2015 Nov 19. Leukemia. 2016. PMID: 26582645 Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous